Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Apple won the case, though was only awarded a nominal $250, which is the smallest amount it was possible for the court to order. In other words, yes Masimo did in infringe Apple’s patents, but there ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Reports Q3 revenue $504.6M, consensus $502.67M. Michelle Brennan, Interim Chief Executive Officer of Masimo (MASI), said, “We are pleased ...

(CNN) — Apple convinced a federal jury on Friday that health monitoring tech company Masimo’s smartwatches infringe two of its design patents. The jury, in Delaware, agreed with Apple that ...

Consensus $3.88. Cuts FY24 revenue view to $2.075B-$2.105B form $2.085B-$2.135B, consensus $2.1B. Published first on TheFly – the ...

Masimo (NASDAQ:MASI) is set to give its latest ... remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures ...

In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes ...

But if Masimo decides to no longer pursue a spinoff of the consumer segment into a publicly traded company, it expects to treat the business as a discontinued operation, Young explained ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.